Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Genital Warts (Condylomata Acuminata) Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Genital Warts (Condylomata Acuminata) Overview | 8 | 1 |
| Genital Warts (Condylomata Acuminata) Therapeutics under Development by Companies | 9 | 1 |
| Genital Warts (Condylomata Acuminata) Pipeline Products Glance | 10 | 2 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Genital Warts (Condylomata Acuminata) Products under Development by Companies | 12 | 1 |
| Genital Warts (Condylomata Acuminata) Companies Involved in Therapeutics Development | 13 | 13 |
| Agilvax, Inc. | 13 | 1 |
| Aviragen Therapeutics, Inc. | 14 | 1 |
| Biogenomics Limited | 15 | 1 |
| BioMAS Ltd. | 16 | 1 |
| Cutanea Life Sciences Inc | 17 | 1 |
| Foamix Pharmaceuticals Ltd. | 18 | 1 |
| G&E Herbal Biotechnology Co., Ltd. | 19 | 1 |
| Laboratories Ojer Pharma S.L. | 20 | 1 |
| LEO Pharma A/S | 21 | 1 |
| Novan, Inc. | 22 | 1 |
| Novartis AG | 23 | 1 |
| Tamir Biotechnology, Inc. | 24 | 1 |
| Zydus Cadila Healthcare Limited | 25 | 1 |
| Genital Warts (Condylomata Acuminata) Therapeutics Assessment | 26 | 9 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 2 |
| Assessment by Molecule Type | 33 | 2 |
| Drug Profiles | 35 | 23 |
| AX-03 Drug Profile | 35 | 2 |
| BTA-074 Drug Profile | 37 | 2 |
| CB-0602 Drug Profile | 39 | 2 |
| human papillomavirus [serotypes 6, 11] (bivalent) vaccine Drug Profile | 41 | 1 |
| human papillomavirus vaccine Drug Profile | 42 | 1 |
| imiquimod Drug Profile | 43 | 1 |
| imiquimod SR Drug Profile | 44 | 1 |
| ingenol mebutate Drug Profile | 45 | 2 |
| interferon alfa-2b Drug Profile | 47 | 1 |
| LFX-453 Drug Profile | 48 | 1 |
| omiganan pentahydrochloride Drug Profile | 49 | 2 |
| PP-210 Drug Profile | 51 | 1 |
| ranpirnase Drug Profile | 52 | 3 |
| SB-206 Drug Profile | 55 | 1 |
| SRT-100 Drug Profile | 56 | 2 |
| Genital Warts (Condylomata Acuminata) Dormant Projects | 58 | 1 |
| Genital Warts (Condylomata Acuminata) Discontinued Products | 59 | 1 |
| Genital Warts (Condylomata Acuminata) Product Development Milestones | 60 | 1 |
| Featured News &Press Releases | 60 | 1 |
| May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206 | 60 | 1 |
| May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA | 60 | 1 |
| Appendix | 61 | 2 |
| Methodology | 61 | 1 |
| Coverage | 61 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Expert Panel Validation | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |